Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0002023658-24-000002
Filing Date
2024-11-12
Accepted
2024-11-12 16:02:19
Documents
72
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bcax-20240930.htm   iXBRL 10-Q 2555955
2 EX-10.7 leaseagreement.htm EX-10.7 193468
3 EX-31.1 exhibit311.htm EX-31.1 10036
4 EX-31.2 exhibit312.htm EX-31.2 9962
5 EX-32.1 exhibit321.htm EX-32.1 7734
11 image_1.jpg GRAPHIC 155
12 image_3.jpg GRAPHIC 858
13 image_4.jpg GRAPHIC 17161
14 image_5.jpg GRAPHIC 140
15 image_6.jpg GRAPHIC 18052
16 image_7.jpg GRAPHIC 438117
  Complete submission text file 0002023658-24-000002.txt   7935777

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20240930.xsd EX-101.SCH 39180
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcax-20240930_cal.xml EX-101.CAL 33680
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcax-20240930_def.xml EX-101.DEF 246456
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20240930_lab.xml EX-101.LAB 537251
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20240930_pre.xml EX-101.PRE 401806
75 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20240930_htm.xml XML 520864
Mailing Address 245 MAIN STREET CAMBRIDGE MA 02142
Business Address 245 MAIN STREET CAMBRIDGE MA 02142 617-785-8308
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42271 | Film No.: 241447816
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)